Targeting the PI3K-AKT-mTOR singnaling network in cancer

Chinese Journal of Cancer

Volumn 32, Issue 5, 2013, Pages 253-265

  Khan, Khurum H ^a   Yap, Timothy A ^a   Yan, Li ^b,c,d   Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c US Chinese Anti Cancer Association   (United States)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Molecular therapeutics; PI3K AKT mTOR; PTEN; RTK; Signaling pathways

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ABI 009; AFURESERTIB; APITOLISIB; AR 42; ARCHEXIN; ATU 027; AZD 2014; AZD 5363; AZD 6482; AZD 8055; BAY 806946; BUPARLISIB; BYL 719; CC 223; CH 5132799; EVEROLIMUS; EXEL 6147; GDC 0068; GSK 2126458; GSK 2141795; GSK 2636771; IDELALISIB; INK 128; KP 372 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OLEANDRIN; PBI 05204; PERIFOSINE; PF 04691502; PF 05212384; PF 4691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RG 7440; RIDAFOROLIMUS; RX 0201; TEMSIROLIMUS; TRICIRIBINE PHOSPHATE; UNCLASSIFIED DRUG; XL 147; XL 765;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC RHINITIS; ASTHMA; BONE METASTASIS; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENICITY; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME MECHANISM; FATIGUE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; INFLAMMATION; KIDNEY CARCINOMA; LEUKEMIA; LIVER CANCER; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG DIFFUSION CAPACITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MELANOMA; MESOTHELIOMA; METASTASIS; MISSENSE MUTATION; MONOTHERAPY; MOOD DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PLEURA EFFUSION; PNEUMONIA; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PTEN GENE; RETINA MACULA DEGENERATION; REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMATIC MUTATION; STOMACH CANCER; THYROID CANCER; TUMOR SUPPRESSOR GENE; VOMITING;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RET; PTEN PHOSPHOHYDROLASE; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84877244768     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10057     Document Type: Review

References (77)

1. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 2009,9:550-562.
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-ki nases as regulators of growth and metabolism. Nat Rev Genet, 2006,7:606-619.
3. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in uman cancers. Cell Cycle, 2004,3:1221-1224.
4. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004,304:554.
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2002,2:489-501.
6. Bader AG, Kang S, Zhao L, et al. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer, 2005,5:921-929.
7. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 2004,428:332-337.
8. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell, 2000,103:253-262.
9. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature, 1990,345:544-547.
10. Dan HC, Sun M, Yang L, et al. Phosphatidylinositol 3-ki nase/ Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem, 2002,277: 35364-35370.
11. Hengstschlager M, Rosner M, Fountoulakis M, et al. Tuberous sclerosis genes regulate cellular 14-3-3 protein levels. Biochem Biophys Res Commun, 2003,312:676-683.
12. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol, 2004,166:213-223.
13. Zhang H, Cicchetti G, Onda H, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest, 2003,112:1223-1233.
14. Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev, 1998,12:3499-3511.
15. Skinner HD, Zheng JZ, Fang J, et al. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia- inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-ki nase/AKT signaling. J Biol Chem, 2004,279:45643-45651.
16. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene, 2003,22:3205-3212.
17. Gupta AK, Cerniglia GJ, Mick R, et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys, 2003,56:846-853.
18. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997,275:1943-1947.
19. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res, 1997,57:5221-5225.
20. Haas-Kogan D, Shalev N, Wong M, et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol, 1998,8:1195-1198.
21. Sun X, Huang J, Homma T, et al. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res, 2009,29: 1739-1743.
22. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/ Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A, 1999,96:1563-1568.
23. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol, 2004,22:2954-2963.
24. Wang S, Gao J, Lei Q, et al. Prostate-s pecific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 2003,4:209-221.
25. Mueller S, Phillips J, Onar-Thomas A, et al. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol, 2012,14:1146-1152.
26. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene, 2008,27:5497-5510.
27. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-ki nase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A, 2005,102:802-807.
28. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 2005,7:561-573.
29. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet, 1999,21:99-102.
30. Bleeker FE, Felicioni L, Buttitta F, et al. AKT1 (E17K) in human solid tumours. Oncogene, 2008,27:5648-5650.
31. Rychahou PG, Kang J, Gulhati P, et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A, 2008,105:20315-20320.
32. Irie HY, Pearline RV, Grueneberg D, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial- mesenchymal transition. J Cell Biol, 2005,171:1023-1034.
33. Davies MA, Stemke-Hale K, Tellez C, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer, 2008,99:1265-1268.
34. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med, 2008,14:1351-1356.
35. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3- kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res, 2008,68:9221-9230.
36. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007,316:1039-1043.
37. Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell, 2005,8:381-392.
38. Edelman G, Bedell C, Shapiro G, et al. A phase I dose-escalation study of XL147(SAR245408), a PI3K inhibitor administered orally to patients(pts) with advanced malignancies. J Clin Oncol, 2010,28:abstr 3004.
39. Hong DS, Bowles DW, Falchook GS, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res, 2012,18:4173-4182.
40. Jimeno A, Herbst RS, Falchook GS, et al. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. J Clin Oncol,2010,28: abstr 3089.
41. Baselga J, Jonge MJD, Rodon J, et al. A first-in-human Phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients(pts) with advanced solid tumors. J Clin Oncol, 2010,28:abstr 3003.
42. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose- escalation study of BKM120, an oral pan-C lass I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol, 2012,30: 282-290.
43. Hoff DDV, LoRusso P, Tibes R, et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol, 2010,28:abstr 2541.
44. Patnaik A MJ, Ramanathan RK, Beeram M, et al. A first-in - human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: results of dose-escalation phase. J Clin Oncol, 2011,29:abstr 3035.
45. MT L. Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-H odgkin lymphoma treated in MTD expansion cohorts. J Clin Oncol, 2012,30:abstr 3019.
46. Aleku M, Schulz P, Keil O, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res, 2008,68:9788-9798.
47. Santel A, Aleku M, Roder N, et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res, 2010,16:5469-5480.
48. Furman RR, Byrd JC, Flinn IW, et al. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-ki nase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol, 2010,28:abstr 3032.
49. Garrett CR, Coppola D, Wenham RM, et al. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-m olecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs, 2011,29:1381-1389.
50. Bidyasar S, Kurzrock R, Falchook GS, et al. A first-in-human phase I trial of PBI-0 5204 (oleandrin), an inhibitor of Akt, FGF-2, NF-Kb, and p70S6K in advanced solid tumor patients. J Clin Oncol, 2009,27: abstr 3537.
51. Cherrin C, Haskell K, Howell B, et al. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther, 2010,9:493-503.
52. Yap TA, Patnaik A, Fearen I, et al. First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. J Clin Oncol, 2010,28:abstr 3009.
53. Yap TA, Yan L, Patnaik A, et al. First-in-m an clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol, 2011,29:4688-4695.
54. Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther, 2012,11:873-887.
55. Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther, 2012,11:873-887.
56. Marshall J, Posey J, Hwang J, et al. A phase I trial of RX-0201 (AKT anti-s ense) in patients with an advanced cancer. J Clin Oncol, 2007,25:abstr 3564.
57. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res, 2010,16: 1033-1041.
58. Unger C, Berdel W, Hanauske AR, et al. First-ti me-in-m an and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer, 2010,46:920-925.
59. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int, 2003,63:917-926.
60. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011,364: 514-523.
61. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer, 2010,116:4256-4265.
62. Yap TA, Garrett MD, Walton MI, et al. Targeting the PI3K-AKT- mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol, 2008,8:393-412.
63. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res, 2006,66:1500-1508.
64. Tan DS, Dumez H, Olmos D, et al. First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. J Clin Oncol, 2010,28:abstr 3006.
65. Burris H, Rodon J, Sharma S, et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients(pts) with advanced solid tumors. J Clin Oncol, 2010,28:abstr 3005.
66. Brana I, LoRusso P, Baselga J, et al. A phase I dose-escalation study of the safety, pharmacokinetics(PK), and pharmacodynamics of XL765(SAR245409), a PI3K/TORC1/ TORC2 inhibitor administered orally to patients(pts) with advanced malignancies. J Clin Oncol, 2010,28:abstr 3030.
67. Dolly S, Wagner AJ, Bendell JC, et al. A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-H odgkin's lymphoma. J Clin Oncol, 2010,28:abstr 3079.
68. Wagner AJ, Bendell JC, Dolly S, et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol, 2011,29:abstr 3020.
69. Mahadevan D, Chiorean EG, Harris WB, et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/ mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer, 2012,48:3319-3327.
70. Blay JY. Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol, 2010,22:280-287.
71. Di Paolo S, Teutonico A, Leogrande D, et al. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol, 2006,17:2236-2244.
72. Crouthamel MC, Kahana JA, Korenchuk S, et al. Mechanism and management of AKT inhibitor-in duced hyperglycemia. Clin Cancer Res, 2009,15:217-225.
73. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation, 2001,72:1244-1250.
74. Kraemer FB, Takeda D, Natu V, et al. Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-s ensitive pathways. Metabolism, 1998,47:555-559.
75. Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-A kt-m TOR pathway. J Clin Oncol, 2012,30:2919-2928.
76. Mueller A, Bachmann E, Linnig M, et al. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-ty pe and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol, 2012,69: 1601-1615.
77. Kwei KA, Baker JB, Pelham RJ. Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection. PLoS One, 2012,7:e46518.